Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial)

Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial)

BackgroundTransient tachypnea of the newborn (TTN), which results from inadequate absorption of fetal lung fluid, is the most common cause of neonatal respiratory distress. Stimulation of β-adrenergic receptors enhances alveolar fluid absorption. Therefore, the β2-adrenergic receptor agonist salbuta...

Full description

Bibliographic Details
Main Authors: Dariusz Madajczak, Thierry Daboval, Ryszard Lauterbach, Beata Łoniewska, Witold Błaż, Tomasz Szczapa, Iwona Sadowska-Krawczenko, Marzena Michalak-Kloc, Helena Sławska, Maria Borszewska-Kornacka, Renata Bokiniec, the REFSAL Study Group
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pediatrics
Subjects:
transient tachypnea
respiratory distress
persistent pulmonary hypertension
neonate
salbutamol
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2022.1060843/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2022.1060843/full

Similar Items